盐酸川芎嗪注射液联合硫酸镁和拉贝洛尔治疗妊娠高血压综合征的临床研究

目的探讨盐酸川芎嗪注射液联合硫酸镁注射液和拉贝洛尔治疗妊娠高血压综合征的临床疗效。方法选取2018年3月—2019年3月武警特色医学中心收治的60例妊娠高血压综合征的患者为研究对象,将患者随机分为对照组和治疗组,每组各30例。对照组患者静脉滴注硫酸镁注射液,30m L加入到5%葡萄糖溶液500mL中,1次/d;同时静脉滴注盐酸拉贝洛尔注射液,50 mg加入到5%葡萄糖溶液250 mL中,1次/d,血压控制后改为口服拉贝洛尔片,100 mg/次,3次/d。治疗组在对照组治疗的基础上静脉滴注盐酸川芎嗪注射液,120 mg加入到5%葡萄糖溶液250 mL中,1次/d。两组患者同步连续治疗14 d。观察两组患者的临床疗效,比较两组的血压、尿蛋白含量、血清学指标基质金属蛋白酶-9(MMP-9)、血管内皮生长因子(VEGF)水平。结果治疗后,对照组和治疗组的总有效率分别为73.3%、93.3%,两组比较差异有统计学意义(P0.05)。治疗后,两组收缩压(SBP)、舒张压(DBP)、尿蛋白均明显下降,同组治疗前后比较差异有统计学意义(P0.05);且治疗组SBP、DBP、尿蛋白明显低于对照组,两组比较差异有统计学意义(P0.05)。治疗后,两组血清MMP-9、VEGF水平均明显升高,同组治疗前后比较差异有统计学意义(P0.05);且治疗后治疗组血清MMP-9、VEGF水平明显高于对照组,两组比较差异均有统计学意义(P0.05)。结论盐酸川芎嗪注射液联合硫酸镁注射液和盐酸拉贝洛尔治疗妊娠高血压综合征具有较好的临床疗效,可降低患者血压和尿蛋白含量,提高患者血清MMP-9、VEGF水平,具有一定的临床推广应用价值。

Clinical study on Ligustrazine Hydrochloride Injection combined with magnesium sulfate and labetalol in treatment of pregnancy-induced hypertension

Objective To investigate the clinical effect of Ligustrazine Hydrochloride Injection combined with Magnesium Sulfate Injection and labetalol in treatment of pregnancy-induced hypertension. Methods Patients (60 cases) with pregnancy-induced hypertension in Characteristic Medical Center of People''s Armed Police from March 2018 to March 2019 were randomly divided into control and treatment groups, and each group had 30 cases. Patients in the control group were iv administered with Magnesium Sulfate Injection, 30 mL added into 5% glucose solution 500 mL, once daily. And patients in the control group were also iv administered with Labetalol Hydrochloride Injection, 50 mg added into 5% glucose solution 250 mL, once daily, and after blood pressure control, patients in the control group were po administered with Labetalol Hydrochloride Tablets, 100 mg/time, three times daily. Patients in the treatment group were iv administered with Ligustrazine Hydrochloride Injection on the basis of the control group, 120 mg added into 5% glucose solution 250 mL, once daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacies were evaluated, and blood pressure, urinary protein content, and serum index levels of MMP-9 and VEGF in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 73.3% and 93.3%, respectively, and there was difference between two groups (P<0.05). After treatment, SBP, DBP, and urine protein in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the serum levels of MMP-9 and VEGF in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the serum index levels in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P<0.05). Conclusion Ligustrazine Hydrochloride Injection combined with Magnesium Sulfate Injection and labetalol has clinical curative effect in treatment of pregnancy induced hypertension, can reduce the blood pressure and urine protein content, and improve the levels of MMP-9 and VEGF, which has a certain clinical application value.